search
Back to results

Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial (ASPIRIN-C3)

Primary Purpose

Atherosclerosis, Cardiovascular Diseases, Drug Effect

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Aspirin
Sponsored by
Tor Biering-Sørensen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atherosclerosis focused on measuring Aspirin, Cardiovascular Disease, Prevention, Circadian Rhythm, Randomized Controlled Trial, Pragmatic, Outcomes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age >=18 years Current chronic treatment with aspirin (as recorded in the Danish National Prescription Registry and confirmed by the participant via questionnaire) Signed informed consent Exclusion Criteria: There are no exclusion criteria for this trial

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Aspirin at bedtime

    Aspirin in the morning

    Arm Description

    Participants randomized to aspirin administration at bedtime will be instructed to take their aspirin at approx. 8PM-12AM.

    Participants randomized to aspirin administration in the morning will be instructed to take their aspirin upon awakening or with their breakfast (approx. 6-10AM).

    Outcomes

    Primary Outcome Measures

    Composite of hospitalization for myocardial infarction, hospitalization for stroke, coronary revascularization, or cardiovascular death

    Secondary Outcome Measures

    Hospitalization for myocardial infarction
    Hospitalization for stroke
    Coronary revascularization
    Cardiovascular death
    All-cause death

    Full Information

    First Posted
    June 22, 2023
    Last Updated
    July 5, 2023
    Sponsor
    Tor Biering-Sørensen
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05932472
    Brief Title
    Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial
    Acronym
    ASPIRIN-C3
    Official Title
    Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    August 1, 2023 (Anticipated)
    Primary Completion Date
    August 1, 2026 (Anticipated)
    Study Completion Date
    August 1, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Tor Biering-Sørensen

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Wide variability in the antiplatelet effects of aspirin may lead to recurrent thromboembolic events. Several pilot studies have suggested potential benefits of taking aspirin at bedtime rather than in the morning. The primary objective of this study is to examine whether aspirin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking aspirin.
    Detailed Description
    The study is a pragmatic, registry-based, open-label, randomized controlled trial combining the utilization of the Danish nationwide health registries and the official Danish electronic letter system (Digital Post/eBoks) into an innovative, decentralized trial requiring no study visits from participants. The nationwide health registries will be used for identification of potential participants and data collection, including baseline information and follow-up data, while the electronic letter system will be used for sending recruitment letters and communicating with participants. Study participants will provide electronic informed consent from home before inclusion and randomization. The trial will include patients currently in aspirin treatment regardless of the presence or absence of established cardiovascular disease. Participants will be randomized 1:1 to either aspirin administration at bedtime or in the morning. The trial is event-driven.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Atherosclerosis, Cardiovascular Diseases, Drug Effect
    Keywords
    Aspirin, Cardiovascular Disease, Prevention, Circadian Rhythm, Randomized Controlled Trial, Pragmatic, Outcomes

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    32706 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Aspirin at bedtime
    Arm Type
    Experimental
    Arm Description
    Participants randomized to aspirin administration at bedtime will be instructed to take their aspirin at approx. 8PM-12AM.
    Arm Title
    Aspirin in the morning
    Arm Type
    Active Comparator
    Arm Description
    Participants randomized to aspirin administration in the morning will be instructed to take their aspirin upon awakening or with their breakfast (approx. 6-10AM).
    Intervention Type
    Drug
    Intervention Name(s)
    Aspirin
    Intervention Description
    Aspirin at currently prescribed dose
    Primary Outcome Measure Information:
    Title
    Composite of hospitalization for myocardial infarction, hospitalization for stroke, coronary revascularization, or cardiovascular death
    Time Frame
    Up to 3 years
    Secondary Outcome Measure Information:
    Title
    Hospitalization for myocardial infarction
    Time Frame
    Up to 3 years
    Title
    Hospitalization for stroke
    Time Frame
    Up to 3 years
    Title
    Coronary revascularization
    Time Frame
    Up to 3 years
    Title
    Cardiovascular death
    Time Frame
    Up to 3 years
    Title
    All-cause death
    Time Frame
    Up to 3 years
    Other Pre-specified Outcome Measures:
    Title
    Bleeding episode requiring hospitalization
    Time Frame
    Up to 3 years
    Title
    Hospitalization for intracranial hemorrhage
    Time Frame
    Up to 3 years
    Title
    Hospitalization for gastrointestinal hemorrhage
    Time Frame
    Up to 3 years
    Title
    Hospitalization for unstable angina
    Time Frame
    Up to 3 years
    Title
    Any arterial revascularization
    Time Frame
    Up to 3 years
    Title
    Any venous thromboembolism
    Time Frame
    Up to 3 years
    Title
    Time of day of hospitalization for myocardial infarction
    Time Frame
    Up to 3 years
    Title
    Time of day of hospitalization for stroke
    Time Frame
    Up to 3 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age >=18 years Current chronic treatment with aspirin (as recorded in the Danish National Prescription Registry and confirmed by the participant via questionnaire) Signed informed consent Exclusion Criteria: There are no exclusion criteria for this trial
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Niklas Dyrby Johansen, MD
    Phone
    +4520204794
    Email
    niklas.dyrby.johansen@regionh.dk
    First Name & Middle Initial & Last Name or Official Title & Degree
    Manan Pareek, MD, PhD
    Phone
    +4525536900
    Email
    mananpareek@dadlnet.dk
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Manan Pareek, MD, PhD
    Organizational Affiliation
    Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    Baseline and endpoint data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor in case of any inquiries.

    Learn more about this trial

    Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial

    We'll reach out to this number within 24 hrs